MURAL ONCOLOGY PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.35 USD | 0.00% |
|
-6.69% | -43.41% |
| 04-04 | Morgan Stanley Initiates Coverage on Mural Oncology With Overweight Rating, $13 Price Target | MT |
| 01-08 | Mural Oncology plc Announces Enhancements to Late-Stage Clinical Trials | CI |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 56.69 | - | - |
| Enterprise Value (EV) 1 | -99.79 | -139.5 | -178.1 |
| P/E ratio | - | - | - |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | 2,175,970 x |
| EV / Revenue | - | - | -6,833,929 x |
| EV / EBITDA | 0.73 x | 1.05 x | 1.22 x |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Price to Book | 0.35 x | 0.77 x | 1.04 x |
| Nbr of stocks (in thousands) | 16,924 | - | - |
| Reference price 2 | 3.350 | 3.350 | 3.350 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net sales | - | - | 26.06 |
| EBITDA 1 | -137 | -132.7 | -145.4 |
| EBIT 1 | -139.2 | -135.1 | -148 |
| Operating Margin | - | - | -567.98% |
| Earnings before Tax (EBT) | - | - | - |
| Net income | - | - | - |
| Net margin | - | - | - |
| EPS | - | - | - |
| Free Cash Flow | - | - | - |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net Debt 1 | - | - | - |
| Net Cash position 1 | 156 | 196 | 235 |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow | - | - | - |
| ROE (net income / shareholders' equity) | -59.6% | -68.9% | -61.3% |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets | - | - | - |
| Book Value Per Share 2 | 9.560 | 4.370 | 3.230 |
| Cash Flow per Share | - | - | - |
| Capex | - | - | - |
| Capex / Sales | - | - | - |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.35
USD
Average target price
13
USD
Spread / Average Target
+288.06%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -43.41% | 56.69M | |
| +8.92% | 114B | |
| +10.48% | 104B | |
| -1.83% | 22.57B | |
| -6.45% | 22.5B | |
| -10.39% | 17.95B | |
| -42.36% | 16.48B | |
| -14.45% | 15.82B | |
| +3.76% | 13.55B | |
| +28.94% | 10.99B |
- Stock Market
- Equities
- MURA Stock
- Financials Mural Oncology plc
